Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07498205 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

Study acronym: APEX-MF
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Aug 8, 2026 to Nov 2026 Eligibility criteria expanded, about 41 words · Study description expanded, about 3 words Show 2 more changesShow less
    • Eligibility criteria expanded, about 41 words
    • Study description expanded, about 3 words
  2. 3 versions Re-verified since Apr 3, 2026, no change to tracked fieldsv2-v4
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.
Trial Details
NCT Number NCT07498205
Lead Sponsor SWOG Cancer Research Network
Collaborators: GlaxoSmithKline
Conditions Myelofibrosis, Myelofibrosis (MF)
Enrollment 268 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov